Alzheimer Disease Clinical Trials

134 studies are recruiting for alzheimer disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. The Gut - PRO Study

   The purpose of this study is to assess the safety and feasibility of an oral probiotic supplement (PS) intervention in individuals with dementia or mild-cognitive impairment (MCI) due to Alzheimer's disease or at risk of dementia due to Alzheimer's disease (AD). 40 participants will be enrolled and…

   Stage

   Phase 1

   Ages

   60 and older

   Site

   University of Wisconsin Hospitals and Clinics, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT07413744 on ClinicalTrials.gov

2. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

   The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of…

   Stage

   Phase 1

   Ages

   50 to 85

   Site

   K2 Medical Research, LLC, Maitland, Florida

   Locations

   10 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06297590 on ClinicalTrials.gov

3. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

   The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

   Stage

   Phase 3

   Ages

   55 and older

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Locations

   62 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07602582 on ClinicalTrials.gov

4. Triage Survey for Neurology Research Eligibility

   TRIAGE-Neuro is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored neurology clinical trials.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Adams Clinical, Watertown, Massachusetts

   Locations

   3 in total

   Run by

   Adams Clinical

   See if you can join NCT06104852 on ClinicalTrials.gov

5. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Gilbert Neurology Partners - PLLC - Avacare, Gilbert, Arizona

   Locations

   296 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

6. Alzheimer's Tau Platform: Master Protocol

   The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This platform trial …

   Stage

   Phase 2

   Ages

   50 to 80

   Site

   Banner Alzheimer's Institute, Phoenix, Arizona

   Locations

   7 in total

   Run by

   Paul S. Aisen

   See if you can join NCT06957418 on ClinicalTrials.gov

7. [18F]PI-2620 Phase 3 Histopathological Study

   This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…

   Stage

   Phase 3

   Ages

   50 and older

   Site

   Barrow Neurological Institute, Phoenix, Arizona

   Locations

   25 in total

   Run by

   Lantheus Biosciences Ltd.

   See if you can join NCT05641688 on ClinicalTrials.gov

8. A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

   The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the …

   Stage

   Phase 1

   Ages

   18 to 85

   Site

   Fortrea Clinical Research Unit, Daytona Beach, Florida

   Locations

   18 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07787182 on ClinicalTrials.gov

9. A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

   The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to th…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Rehabilitation & Neurological Services, Huntsville, Alabama

   Run by

   Eli Lilly and Company

   See if you can join NCT06566170 on ClinicalTrials.gov

10. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

    Stage

    Phase 4

    Ages

    50 and older

    Site

    Progeny Psychiatric Clinic - Irvine, Irvine, California

    Locations

    22 in total

    Run by

    Alpha Cognition, Inc

    See if you can join NCT07633470 on ClinicalTrials.gov

11. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

    Stage

    Phase 3

    Ages

    55 to 90

    Site

    Imaging Endpoints, Scottsdale, Arizona

    Locations

    252 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06937229 on ClinicalTrials.gov

12. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Stage

    Phase 3

    Ages

    55 to 90

    Site

    Imaging Endpoints, Scottsdale, Arizona

    Locations

    162 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07011732 on ClinicalTrials.gov

13. Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

    This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairmen…

    Stage

    Phase 2

    Ages

    55 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Massachusetts General Hospital

    See if you can join NCT07236190 on ClinicalTrials.gov

14. A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

    The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Pa…

    Stage

    Phase 1

    Ages

    18 to 85

    Site

    Fortrea Clinical Research Unit, Daytona Beach, Florida

    Locations

    18 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07787169 on ClinicalTrials.gov

15. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

    This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

    Stage

    Phase 2

    Ages

    55 to 80

    Site

    Banner Alzheimer's Institute, Phoenix, Arizona

    Locations

    39 in total

    Run by

    Lighthouse Pharmaceuticals, Inc.

    See if you can join NCT06847321 on ClinicalTrials.gov

16. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

    Stage

    Phase 2

    Ages

    55 to 90

    Site

    University of Alabama - Huntsville Regional Medical Campus, Huntsville, Alabama

    Locations

    77 in total

    Run by

    Celgene

    See if you can join NCT06808984 on ClinicalTrials.gov

17. DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

    This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection. The study will evaluate how well the vaccine is tolerated and whether it produces…

    Stage

    Phase 1

    Ages

    40 to 65

    Site

    Palm Springs Community Health Center, Miami Lakes, Florida

    Run by

    Nuravax, Inc.

    See if you can join NCT07142278 on ClinicalTrials.gov

18. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

    Stage

    Phase 2

    Ages

    55 and older

    Site

    Advanced Research Center, Inc, Anaheim, California

    Locations

    69 in total

    Run by

    Intra-Cellular Therapies, Inc.

    See if you can join NCT06540833 on ClinicalTrials.gov

19. A Study of LY3439539 in Participants With Alzheimer's Disease

    The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.

    Stage

    Phase 1

    Ages

    50 to 85

    Site

    Austin Health - Heidelberg Repatriation Hospital, Ivanhoe,

    Locations

    15 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07598370 on ClinicalTrials.gov

20. Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation

    The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidate AD-related pathophysiology and set groundwork for the dev…

    Stage

    Not phased

    Ages

    50 to 100

    Site

    111 Cummington Mall. Room 264, Boston, Massachusetts

    Run by

    Boston University Charles River Campus

    See if you can join NCT06094192 on ClinicalTrials.gov

21. PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

    The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Perelman Center for Advance Medicine, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT05456503 on ClinicalTrials.gov

22. Music for Pain and Dementia

    This study aims to provide mechanistic insights into how group drumming as a music-based intervention (MBI) affects pain responses and nociceptive function in individuals with Alzheimer's Disease (AD), mild dementia or mild cognitive impairment (MCI). Heart rate (HR), heart rate variability (HRV), …

    Stage

    Not phased

    Ages

    50 to 80

    Site

    Connecticut Mental Health Clinic, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT07602283 on ClinicalTrials.gov

23. Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease

    An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over 120 days.…

    Stage

    Not phased

    Ages

    50 to 100

    Site

    Hackensack Medical Center, Hackensack, New Jersey

    Run by

    Herrick Medical LLC

    See if you can join NCT05295615 on ClinicalTrials.gov

24. Making Connections Thru Music

    Healthcare systems around the world, including within the United States, have long-established shortages of trained caregivers. The American Health Care Association states that "the health care system has experienced a shortage of trained caregivers for critical roles for some time." This scarcity …

    Stage

    Not phased

    Ages

    18 to 103

    Site

    Hopeful Aging, Winchester, Massachusetts

    Locations

    2 in total

    Run by

    Hopeful Aging

    See if you can join NCT06079216 on ClinicalTrials.gov

25. The BRAIN App (Phase 2 SBIR)

    There are currently 6.7 million Americans living with dementia and, without significant breakthroughs, this figure will double to 12.7 million by 2050. There are about 46,000 long-term care (LTC) facilities in the U.S. More than half of LTC residents have some form of dementia (Alzheimer's Associat…

    Stage

    Not phased

    Ages

    65 and older

    Site

    Hopeful Aging, Winchester, Massachusetts

    Run by

    Hopeful Aging

    See if you can join NCT06298474 on ClinicalTrials.gov